Biomedtracker

Report Library

Follicular Lymphoma KOL Interview – US

September 30, 2022

This interview with a US-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Future trends and unmet needs are also discussed. Key drug classes highlighted include anti-CD20 antibodies (Rituxan and Gazyva), immunomodulators (Revlimid), autologous CAR-T therapies (Yescarta and Kymriah), CD20 x CD3 bispecifics (Lunsumio), BTK inhibitors (Imbruvica and Brukinsa), EZH2 inhibitors (Tazverik), PI3 kinase inhibitors (Copiktra, Zydelig, Aliqopa, and zandelisib), and anti-CD19 antibodies (Monjuvi).

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered:

Follicular Lymphoma (FL)

Additional Resources: